{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T22:19:33Z","timestamp":1780352373588,"version":"3.54.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NIH","award":["P50HD103536"],"award-info":[{"award-number":["P50HD103536"]}]},{"name":"NIH","award":["U01NS101946"],"award-info":[{"award-number":["U01NS101946"]}]},{"name":"NIH","award":["R01NS060022"],"award-info":[{"award-number":["R01NS060022"]}]},{"DOI":"10.13039\/100012233","name":"Abeona Therapeutics","doi-asserted-by":"publisher","award":["n\/a"],"award-info":[{"award-number":["n\/a"]}],"id":[{"id":"10.13039\/100012233","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005468","name":"Batten Disease Support and Research Association","doi-asserted-by":"publisher","award":["Batten Disease Support and Research Association"],"award-info":[{"award-number":["Batten Disease Support and Research Association"]}],"id":[{"id":"10.13039\/100005468","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011516","name":"Beyond Batten Disease Foundation","doi-asserted-by":"publisher","award":["Beyond Batten Disease Foundation"],"award-info":[{"award-number":["Beyond Batten Disease Foundation"]}],"id":[{"id":"10.13039\/100011516","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Noah's Hope-Hope 4 Bridget","award":["Noah's Hope-Hope 4 Bridget"],"award-info":[{"award-number":["Noah's Hope-Hope 4 Bridget"]}]},{"name":"Our Promise to Nicholas","award":["Our Promise to Nicholas"],"award-info":[{"award-number":["Our Promise to Nicholas"]}]},{"name":"University of Rochester Child Neurology Research Fund","award":["University of Rochester Child Neurology Research Fund"],"award-info":[{"award-number":["University of Rochester Child Neurology Research Fund"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>The neuronal ceroid lipofuscinoses (Batten disease) are rare neurodegenerative lysosomal storage diseases principally of childhood onset and an autosomal recessive inheritance pattern. Cognitive regression is a hallmark of the disease, and has been characterized as part of the University of Rochester Batten Center\u2019s prospective longitudinal natural history. The objective of the present study was to establish convergent validity of the two most recent versions of the Wechsler Intelligence Scale for Children in this population (WISC-IV, 2003; WISC-V, 2014) due to anticipated eventual obsolescence of WISC-IV. 18 children and young adults (12 males, 6 females) with a genetically confirmed NCL diagnosis were administered selected subtests from the WISC-IV and WISC-V. We used bivariate correlations and repeated measures ANOVA between matching subtests across these two WISC versions to determine convergence of the measures.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>WISC-IV and WISC-V verbal subtests were strongly correlated with one another and mean age-adjusted scores for comparable subtests on WISC-IV vs. WISC-V were not significantly different from one another.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>Overall, the minimal performance differences on the two measures supports combining WISC-IV and WISC-V datasets for larger-scale analyses of the neurocognitive natural history of NCL disorders.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13023-025-03923-w","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T15:53:54Z","timestamp":1754582034000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Wechsler intelligence scale for children, fourth and fifth editions perform comparably in children with Batten disease"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5992-4297","authenticated-orcid":false,"given":"Heather R.","family":"Adams","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika F.","family":"Augustine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Bonifacio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Vierhile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Mink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"3923_CR1","doi-asserted-by":"publisher","first-page":"754045","DOI":"10.3389\/fneur.2021.754045","volume":"12","author":"E Gardner","year":"2021","unstructured":"Gardner E, Mole S. The genetic basis of phenotypic hereogeneity in the neuronal ceroid lipofuscinoses. Front Neurol. 2021;12:754045. https:\/\/doi.org\/10.3389\/fneur.2021.754045.","journal-title":"Front Neurol"},{"issue":"11","key":"3923_CR2","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s40265-017-0771-8","volume":"77","author":"A Markham","year":"2017","unstructured":"Markham A. Cerliponase alfa: first global approval. Drugs Jul. 2017;77(11):1247\u20139. https:\/\/doi.org\/10.1007\/s40265-017-0771-8.","journal-title":"Drugs Jul"},{"issue":"9","key":"3923_CR3","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1177\/0883073813494268","volume":"28","author":"JW Mink","year":"2013","unstructured":"Mink JW, Augustine EF, Adams HR, Marshall FJ, Kwon JM. Classification and natural history of the neuronal ceroid lipofuscinoses. Article. J Child Neurol Sep. 2013;28(9):1101\u20135. https:\/\/doi.org\/10.1177\/0883073813494268.","journal-title":"J Child Neurol Sep"},{"key":"3923_CR4","doi-asserted-by":"publisher","first-page":"2237","DOI":"10.1016\/j.bbadis.2015.05.011","volume":"1852","author":"SE Mole","year":"2015","unstructured":"Mole SE, Cotman SL. Genetics of the neuronal ceroid lipofuscinoses (Batten disease). Biochim Biophys Acta Oct. 2015;1852:2237\u201341. https:\/\/doi.org\/10.1016\/j.bbadis.2015.05.011. (10 Pt B).","journal-title":"Biochim Biophys Acta Oct"},{"issue":"1","key":"3923_CR5","first-page":"1","volume":"7","author":"A Schulz","year":"2013","unstructured":"Schulz A, Kohlschutter A. NCL disorders: frequent causes of childhood dementia. Iran J Child Neurol Winter. 2013;7(1):1\u20138.","journal-title":"Iran J Child Neurol Winter"},{"issue":"2","key":"3923_CR6","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1212\/WNL.0b013e31825f0547","volume":"79","author":"R Williams","year":"2012","unstructured":"Williams R, Mole S. New nomenclature and classification scheme for the neuronal ceroid lipofuscinoses. Neurology. 2012;79(2):183\u201391.","journal-title":"Neurology"},{"key":"3923_CR7","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/ajmg.10660","volume":"112","author":"R Steinfeld","year":"2002","unstructured":"Steinfeld R, Heim P, von Gregory H, Meyer K, Ullrich K, Goebel HH, Kohlsch\u00fctter A. Late infantile neuronal ceroid lipofuscinosis: quantitative description of the clinical course in patients with CLN2 mutations. Am J Med Genet. 2002;112:347\u201354.","journal-title":"Am J Med Genet"},{"issue":"8","key":"3923_CR8","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/S2352-4642(18)30179-2","volume":"2","author":"M Nickel","year":"2018","unstructured":"Nickel M, Simonati A, Jacoby D, et al. Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. Lancet Child Adolesc Health Aug. 2018;2(8):582\u201390. https:\/\/doi.org\/10.1016\/S2352-4642(18)30179-2.","journal-title":"Lancet Child Adolesc Health Aug"},{"issue":"5","key":"3923_CR9","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/0883073807302603","volume":"22","author":"HR Adams","year":"2007","unstructured":"Adams HR, Kwon J, Marshall FJ, de Blieck EA, Pearce DA, Mink JW. Neuropsychological symptoms of juvenile-onset Batten disease: experiences from 2 studies. J Child Neurol May. 2007;22(5):621\u20137. https:\/\/doi.org\/10.1177\/0883073807302603.","journal-title":"J Child Neurol May"},{"issue":"9","key":"3923_CR10","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1177\/0883073813494813","volume":"28","author":"HR Adams","year":"2013","unstructured":"Adams HR, Mink JW. Neurobehavioral features and natural history of juvenile neuronal ceroid lipofuscinosis (Batten disease). J Child Neurol Sep. 2013;28(9):1128\u201336. https:\/\/doi.org\/10.1177\/0883073813494813.","journal-title":"J Child Neurol Sep"},{"issue":"1","key":"3923_CR11","first-page":"8","volume":"45","author":"S Lamminranta","year":"2001","unstructured":"Lamminranta S, \u00c5berg LE, Autti T, Moren R, Laine T, Kaukoranta J, Santavuori P. Neuropsychological test battery in the follow-up of patients with juvenile neuronal ceroid lipofuscinosis. J Intellect Disabil Res. 2001;45(1):8\u201317.","journal-title":"J Intellect Disabil Res"},{"issue":"4","key":"3923_CR12","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1177\/0883073815600863","volume":"31","author":"SN Ragbeer","year":"2016","unstructured":"Ragbeer SN, Augustine EF, Mink JW, Thatcher AR, Vierhile AE, Adams HR. Remote assessment of cognitive function in juvenile neuronal ceroid lipofuscinosis (Batten disease): A pilot study of feasibility and reliability. J Child Neurol Mar. 2016;31(4):481\u20137. https:\/\/doi.org\/10.1177\/0883073815600863.","journal-title":"J Child Neurol Mar"},{"key":"3923_CR13","doi-asserted-by":"publisher","unstructured":"Elmerskog B, T\u00f8ssebro AG, Atkinson R, Rokne S, Cole B, Ockelford A. Overview of advances in educational and social supports for young persons with NCL disorders. Biochim Biophys Acta Mol Basis Dis. 2019;1866(9). https:\/\/doi.org\/10.1016\/j.bbadis.2019.05.016.","DOI":"10.1016\/j.bbadis.2019.05.016"},{"key":"3923_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.pediatrneurol.2021.04.002","volume":"120","author":"EF Augustine","year":"2021","unstructured":"Augustine EF, Adams HR, de Los Reyes E, et al. Management of CLN1 disease: international clinical consensus. Pediatr Neurol Jul. 2021;120:38\u201351. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2021.04.002.","journal-title":"Pediatr Neurol Jul"},{"issue":"9","key":"3923_CR15","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1177\/0883073813494813","volume":"28","author":"HR Adams","year":"2013","unstructured":"Adams HR, Mink JW, University of Rochester Batten Center Study G. Neurobehavioral features and natural history of juvenile neuronal ceroid lipofuscinosis (Batten disease). J Child Neurol Sep. 2013;28(9):1128\u201336. https:\/\/doi.org\/10.1177\/0883073813494813.","journal-title":"J Child Neurol Sep"},{"issue":"2","key":"3923_CR16","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.ymgme.2012.11.170","volume":"108","author":"JW Mink","year":"2013","unstructured":"Mink JW, Augustine EF, Marshall FJ, Adams HR, Kwon JM, Vierhile A, de Blieck EA. The natural history of juvenile Batten disease (JNCL; CLN3 disease). Mol Genet Metab Feb. 2013;108(2):S66\u201366. https:\/\/doi.org\/10.1016\/j.ymgme.2012.11.170.","journal-title":"Mol Genet Metab Feb"},{"issue":"1","key":"3923_CR17","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1111\/cdev.13675","volume":"93","author":"E Giangrande","year":"2022","unstructured":"Giangrande E, Beam C, Finkel D, Davis D, Turkheimer E. Genetically informed, multilevel analysis of the Flynn effect across four decades and three WISC versions. Child Dev. 2022;93(1):e47\u201358.","journal-title":"Child Dev"},{"key":"3923_CR18","doi-asserted-by":"crossref","unstructured":"Wechsler D. Wechsler intelligence scale for Children - Fourth edition (WISC-IV). The Psychological Corporation; 2003.","DOI":"10.1037\/t15174-000"},{"key":"3923_CR19","doi-asserted-by":"crossref","unstructured":"Wechsler D. Wechsler intelligence scale for Children - Fifth edition (WISC-V). The Psychological Corporation; 2014.","DOI":"10.1037\/t79359-000"},{"key":"3923_CR20","unstructured":"Wechsler D. WISC-V: technical and interpretive manual. Pearson; 2014."},{"issue":"2","key":"3923_CR21","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1080\/15305050701193587","volume":"7","author":"J Flynn","year":"2007","unstructured":"Flynn J, Weiss L. American IQ gains from 1932 to 2002: the WISC subtests and educational progress. Int J Test. 2007;7(2):209\u201324.","journal-title":"Int J Test"},{"issue":"1\u20132","key":"3923_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.ymgme.2020.08.007","volume":"131","author":"J van der Lee","year":"2020","unstructured":"van der Lee J, Morton J, Adams H, et al. Therapy development for the mucopolysaccharidoses: updated consensus recommendations for neuropsychological endpoints. Mol Genet Metab Sep-Oct. 2020;131(1\u20132):181\u201396. https:\/\/doi.org\/10.1016\/j.ymgme.2020.08.007.","journal-title":"Mol Genet Metab Sep-Oct"},{"issue":"2","key":"3923_CR23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cct.2013.04.004","volume":"35","author":"EA de Blieck","year":"2013","unstructured":"de Blieck EA, Augustine EF, Marshall FJ, et al. Methodology of clinical research in rare diseases: development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates. Contemporary Clin Trials Jul. 2013;35(2):48\u201354. https:\/\/doi.org\/10.1016\/j.cct.2013.04.004.","journal-title":"Contemporary Clin Trials Jul"},{"key":"3923_CR24","unstructured":"Statistica. Version 13.3. TIBCO Software Inc.; 2017."},{"issue":"3","key":"3923_CR25","doi-asserted-by":"publisher","first-page":"e201965","DOI":"10.1001\/jamanetworkopen.2020.1965","volume":"3","author":"A Mitani","year":"2020","unstructured":"Mitani A, Haneuse S. Small data challenges of studying rare diseases. JAMA Netw Open. 2020;3(3):e201965. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.1965.","journal-title":"JAMA Netw Open"},{"key":"3923_CR26","unstructured":"United States Food and Drug Administration. Rare Diseases: Natural History Studies for Drug Development - Guidance for Industry. Accessed 03 Jan 2022."},{"issue":"1","key":"3923_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ymgme.2021.03.002","volume":"133","author":"EG Shapiro","year":"2021","unstructured":"Shapiro EG, Eisengart JB. The natural history of neurocognition in MPS disorders: A review. Mol Genet Metab May. 2021;133(1):8\u201334. https:\/\/doi.org\/10.1016\/j.ymgme.2021.03.002.","journal-title":"Mol Genet Metab May"},{"issue":"2","key":"3923_CR28","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ymgme.2017.05.004","volume":"121","author":"JH van der Lee","year":"2017","unstructured":"van der Lee JH, Morton J, Adams HR, et al. Cognitive endpoints for therapy development for neuronopathic mucopolysaccharidoses: results of a consensus procedure. Mol Genet Metab Jun. 2017;121(2):70\u20139. https:\/\/doi.org\/10.1016\/j.ymgme.2017.05.004.","journal-title":"Mol Genet Metab Jun"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03923-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03923-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03923-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T17:33:36Z","timestamp":1757352816000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03923-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3923"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03923-w","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"17 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was conducted under a study protocol approved by the University of Rochester Research Subjects Review Board (RSRB Study00001970). Parents \/ legal guardians provided written permission for the participation of the affected individual; the requirement to obtain assent (from children) and informed consent (from adults) with Batten disease was waived by the RSRB due to lack of capacity resulting from the cognitive impairments of the affected individuals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable; no individually identifying data is presented.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Heather Adams: Dr. Adams has received payment from Abeona Therapeutics, Biogen, and Critical Path Institute (consultant), from PCORI (past member of PCORI Rare Disease Advisory panel), from the National MPS Society (Master Class faculty member; Delphi panel participant) that is unrelated to the present work, and has received funding from the NIH and from the Batten Disease Support, Research, and Advocacy (BDSRA) Foundation for research that is indirectly related to the present work. Erika Augustine: Dr. Augustine has served as a DSMB member for PTC therapeutics, has received grant funding from the NIH, Neurogene Inc, the Beyond Batten Disease Foundation, and the BDSRA Foundation and consulting funds from Latus Bio. Jonathan Mink: Dr. Mink has served as a DSMB member for PTC Therapeutics and Applied Therapeutics. He is a Central Rater for Emalex. He has served as a paid consultant to the Beyond Batten Disease Foundation and Theranexus, Inc, Neurogene, Inc, and Spark Therapeutics. He has served as Chair (unpaid) to the BDSRA Center of Excellence Overight Committee. He has received funding for research that is indirectly related to this work. Kristen Bonifacio: none. Alyssa Collins: none. Amy E Vierhile: none.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"413"}}